Fifth Third Bancorp
ESPR

Fifth Third Bancorp’s Esperion Therapeutics ESPR Stock Holding History

Fifth Third Bancorp’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-523
Closed -$1.43K – 4375
2026
Q1 		$1.43K Buy
+523
New +$1.66K ﹤0.01% 4089
2021
Q4 		– Sell
-50
Closed -$1K – 2695
2021
Q3 		$1K Hold
50
– – ﹤0.01% 2562
2021
Q2 		$1K Hold
50
– – ﹤0.01% 2380
2021
Q1 		$1K Hold
50
– – ﹤0.01% 2363
2020
Q4 		$1K Hold
50
– – ﹤0.01% 2283
2020
Q3 		$2K Hold
50
– – ﹤0.01% 2032
2020
Q2 		$3K Hold
50
– – ﹤0.01% 1930
2020
Q1 		$2K Buy
+50
New +$2.64K ﹤0.01% 1969
2015
Q4 		– Sell
-2,752
Closed -$65K – 2779
2015
Q3 		$65K Buy
+2,752
New +$173K ﹤0.01% 1311

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Fifth Third Bancorp's ESPR Position: Q2 2026 in Review

Fifth Third Bancorp sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 523 shares — an estimated $1.43K sold.

Fifth Third Bancorp first reported a position in ESPR in Q3 2015 and held it in 9 quarters. The position peaked at $65K in Q3 2015. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Fifth Third Bancorp reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fifth Third Bancorp sold 523 Esperion Therapeutics shares in Q2 2026, an estimated $1.43K.
  • Fifth Third Bancorp first reported a position in Esperion Therapeutics in Q3 2015 and held it in 9 quarters.
  • Fifth Third Bancorp's Esperion Therapeutics position peaked at $65K in Q3 2015.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.